fashion -WSS

fashion

author：hotspot 2025-10-01 02:16:33 - browse：9219

Metastatic Melanoma Cells – cancer research coverage from STAT — Metastatic melanoma cells NCI/NIH

Cancer drugs can burn through tumors like a wildfire, killing off the vast majority of malignant cells. But a few stubborn cells often end up surviving, seeding a recurrence of the disease. The prevailing theory behind this drug resistance is built on natural selection: Among the vast and genetically diverse population of cancer cells in a tumor, some have random mutations that help these cells survive an onslaught.

“But this is not the full picture,” said Yogesh Goyal, a cancer researcher at Northwestern University. Goyal and his colleagues at the University of Pennsylvania demonstrated in a series of experiments that cancer cells can survive treatments just by having certain genes turned on, even if they were nearly genetically identical to cancer cells that died but had activated different genes.

“We think this work stands to really change how we think about therapy resistance,” said Arjun Raj, the study’s co-senior author and a bioengineer at the University of Pennsylvania.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Biogen Alzheimer’s drug launch off to slow start

WSS

For Medicare Advantage, Democrats want stronger protections around AI

Goldman Sachs launches $650M fund for life science investments

How digital tools helped lower hypertension in marginalized patients

Ahead of JPM, here's who's profiting most in health care

How digital tools helped lower hypertension in marginalized patients

Readout LOUD podcast: How biotech is using artificial intelligence

hotspot

fashion

knowledge

Heart attack and stroke risk calculators need revising

The biotech scorecard for Q1: 17 stock

ChatGPT in medicine: STAT answers readers' burning questions

Vaccine advisory panel ACIP left half staffed by HHS

Medical leaders decry Supreme Court decision on affirmative action

Gilead might be held responsible for not developing a drug

The high cost of giving birth even with insurance

For Medicare Advantage, Democrats want stronger protections around AI

BioMarin wins approval for gene therapy to treat hemophilia A

UCB departs biotech trade group BIO

entertainment

Readout LOUD podcast: How biotech is using artificial intelligence

Vaccine advisory panel ACIP left half staffed by HHS

U.K. sequencing study surfaces new findings about tumor DNA

Videos point to link between seizures and unexplained toddler deaths

PhRMA lawsuit over Medicare drug price negotiation tossed

J&J to buy cancer drug developer Ambrx Biopharma

leisure time

explore

hotspot

hotspot